Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and radiation therapy in relapsed or refractory multiple myeloma
NCT03267888Phase 2Completed
- Sponsor
- Emory University
- Start
- May 2018
- Primary completion
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in multiple myeloma (MM), sponsored by Emory University. Primary endpoint: Adverse Events at 12 months. Started May 2018; status: completed.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03267888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03267888.